41. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Issue 3 (7th October 2016) Authors: de Souza, Jonas A.; Yap, Bonnie J.; Wroblewski, Kristen; Blinder, Victoria; Araújo, Fabiana S.; Hlubocky, Fay J.; Nicholas, Lauren H.; O'Connor, Jeremy M.; Brockstein, Bruce; Ratain, Mark J.; Daugherty, Christopher K.; Cella, David Journal: Cancer Issue: Volume 123:Issue 3(2017) Page Start: 476 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
42. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. (3rd October 2018) Authors: House, Larry; Seminerio, Michael J.; Mirkov, Snezana; Ramirez, Jacqueline; Skor, Maxwell; Sachleben, Joseph R.; Isikbay, Masis; Singhal, Hari; Greene, Geoffrey L.; Vander Griend, Donald; Conzen, Suzanne D.; Ratain, Mark J. Journal: Xenobiotica Issue: Volume 48:Number 10(2018:Oct.) Page Start: 973 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
43. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. Issue 9 (20th March 2021) Authors: Tannock, Ian F.; Ratain, Mark J.; Goldstein, Daniel A.; Lichter, Allen S.; Rosner, Gary L.; Saltz, Leonard B. Journal: Journal of clinical oncology Issue: Volume 39:Issue 9(2021) Page Start: 950 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
44. Oncology Drug Prescribing: The Influences of Greed and Fear. Issue 9 (14th September 2022) Authors: Ratain, Mark J. Journal: JCO oncology practice Issue: Volume 18:Issue 9(2022) Page Start: e1384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
45. Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Issue 9 (11th June 2020) Authors: Peer, Cody J.; Goldstein, Daniel A.; Goodell, Jennifer C.; Nguyen, Ryan; Figg, William D.; Ratain, Mark J. Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 9(2020) Page Start: 1769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
46. Patient insights on features of an effective pharmacogenomics patient portal. Issue 9 (December 2020) Authors: Truong, Tien M.; Lipschultz, Elizabeth; Schierer, Emily; Danahey, Keith; Ratain, Mark J.; O'Donnell, Peter H. Journal: Pharmaocogenetics and genomics Issue: Volume 30:Issue 9(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
47. Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). (4th December 2019) Authors: Sharma, Manish R.; Mehrotra, Shailly; Gray, Elizabeth; Wu, Kehua; Barry, William T.; Hudis, Clifford; Winer, Eric P.; Lyss, Alan P.; Toppmeyer, Deborah L.; Moreno‐Aspitia, Alvaro; Lad, Thomas E.; Velasco, Mario; Overmoyer, Beth; Rugo, Hope S.; Ratain, Mark J.; Gobburu, Jogarao V. Journal: Journal of clinical pharmacology Issue: Volume 60:Number 4(2020) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
48. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Issue 9 (December 2021) Authors: Patel, Jai N.; Jiang, Chen; Owzar, Kouros; Mulkey, Flora; Luzum, Jasmine A.; Mamon, Harvey J.; Haller, Daniel G.; Dragovich, Tomislav; Alberts, Steven R.; Bjarnason, Georg; Willet, Christopher G.; Niedzwiecki, Donna; Enzinger, Peter; Ratain, Mark J.; Fuchs, Charles; McLeod, Howard L. Journal: Pharmaocogenetics and genomics Issue: Volume 31:Issue 9(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
49. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. (5th January 2022) Authors: Peer, Cody J.; Heiss, Brian L.; Goldstein, Daniel A.; Goodell, Jennifer C.; Figg, William D.; Ratain, Mark J. Journal: Journal of clinical pharmacology Issue: Volume 62:Number 4(2022) Page Start: 532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
50. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. (October 2019) Authors: Jones, Robin L.; Ratain, Mark J.; O'Dwyer, Peter J.; Siu, Lillian L.; Jassem, Jacek; Medioni, Jacques; DeJonge, Maja; Rudin, Charles; Sawyer, Michael; Khayat, David; Awada, Ahmad; de Vos-Geelen, Judith M.P.G.M.; Evans, T.R. Jeffry; Obel, Jennifer; Brockstein, Bruce; DeGreve, Jacques; Baurain, Jea... Journal: European journal of cancer Issue: Volume 120(2019) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗